Navigation Links
Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
Date:12/5/2011

ne Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease, or CAD. Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BLyS, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more information, please visit www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2010 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2011. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2011 Third Quarter Financial Results and Operational Update
2. Anthera Announces Last Patient Enrolled in PEARL-SC Study
3. Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
4. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
5. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
6. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
7. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
8. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
9. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
10. Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
11. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 ... Market Research Report on Global and China Lysine ... is a professional and the deep research report ... introduces Lysine basic information including definition, classification specifications, ... as US, Europe , ...
(Date:4/17/2015)... 17, 2015 Inivata, a ... that their presence at the 2015 American Association for Cancer ... co-founder Nitzan Rosenfeld and a poster presentation. ... th - 22 nd . The presentation, ... , forms part of a session on ...
(Date:4/17/2015)... CVS Health Corporation (NYSE: CVS ) ... 1, 2015, at 8:30 a.m. (EDT) with analysts and ... An audio webcast of the conference call will ... the CVS Health website for all interested parties. To ... will be archived and available on the web site ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2
... , DES MOINES, Iowa, Oct. 12 Briggs, a ... reduce operating costs in the home care market, today ... mandated by the Centers for Medicare & Medicaid Services ... proprietary documentation for all OASIS assessment forms as well ...
... 12 The University of Kansas Hospital has deployed ... provide physicians, nurses, and pharmacy staff in its neonatal ... and reference information. , The University of ... specializes in heart disease, cancer treatment and prevention, neurology, ...
Cached Medicine Technology:Regulatory Leader in OASIS Documentation Introduces OASIS-C Products 2University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety 2University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety 3
(Date:4/17/2015)... Riviera Magazine has featured board ... the Gallery of Cosmetic Surgery in Newport Beach, California ... The publication focused on his expertise in the lower ... eyelid surgery, laser resurfacing and rhinoplasty. , Dr. Sadati’s ... resulted in thousands of satisfied patients across the globe. ...
(Date:4/17/2015)... 17, 2015 From the day Dr. Todd ... Texas non-profit organization has empowered young people to create meaningful ... bring fresh water and the Gospel to all of ... Between March 17 and 27, students, faculty and staff raised ... with fresh water and the Good News of Jesus. ...
(Date:4/17/2015)... 17, 2015 Enthusiasts of gourmet cuisine and ... April 25, 2015. The event will be held in the ... (201 Monroe Ave NW, Grand Rapids, MI 49503) and will ... Michigan area. Patrons are encouraged to savor the food and ... , This year’s event will feature seven chefs, including:, ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Testosterone ... this class of prescription medications increases the likelihood ... stroke or other life-threatening cardiovascular event continue to ... District Court, Northern District of Illinois. According to ... Judicial Panel on Multidistrict Litigation (JPML) on April ...
(Date:4/17/2015)... Francisco, CA (PRWEB) April 17, 2015 The American ... House event and Free Application Day on April 29. The event ... ACTCM Pioneer Square, located at 555 DeHaro St. in San Francisco, ... 11 a.m. – Check in at the DeHaro campus (room F), ... – Tour of campus, Noon – Light lunch with current students, ...
Breaking Medicine News(10 mins):Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 3Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 4Health News:American College of Traditional Chinese Medicine Hosts Open House 2
... By Serena Gordon HealthDay Reporter , TUESDAY, Oct. ... an advance directive may raise the odds that you,ll receive ... care, a new study indicates. An advance directive, sometimes ... your wishes for the type of care you would like ...
... By Randy Dotinga HealthDay Reporter , TUESDAY, Oct. 4 ... develop breast cancer tend to have more advanced cases than women ... statistics are adjusted for factors such as age, men with breast ... are. The findings shed light on a rare disease in ...
... News) --, People may be learning while they sleep, dramatically ... Although the effects on memory vary greatly and ... findings reinforce the need for a good night,s sleep -- ... the U.S. National Sleep Foundation. "We speculate that we ...
... , TUESDAY, Oct. 4 (HealthDay News) -- ... a recurrence of the disease and improve their overall ... The group pointed out that physical activity has many ... reduced fatigue and improved mood. To help mark ...
... Salamon HealthDay Reporter , TUESDAY, Oct. 4 (HealthDay ... of nature versus nurture, it appears that kids unlucky enough ... sunnier outlooks when they,re parented in a warm, positive manner. ... through 15 with a gene variation predisposing them to lower ...
... at Virginia G. Piper Cancer Center Clinical Trials at ... participate in a clinical trial to determine the safety, ... combination consisting of a standard drug called gemcitabine and ... cancer. The results of this study, ...
Cached Medicine News:Health News:Advance Directives Might Curb Cost of End-of-Life Care 2Health News:Advance Directives Might Curb Cost of End-of-Life Care 3Health News:Breast Cancer Appears Less Deadly for Men Than Women 2Health News:Exercise Tips for Breast Cancer Survivors 2Health News:Happy Kids a Product of Genes, Parenting, Study Finds 2Health News:Happy Kids a Product of Genes, Parenting, Study Finds 3Health News:TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients 2
... is an endoscopic urethral implant for ... Upon implantation, the Tegress™ Implant solution ... in a Dimethyl Sulfoxide (DMSO) carrier ... reinforces the integrity of the urethras ...
... (VZ) test system is intended ... detection of VZ IgG antibody ... indirect fluorescent antibody (IFA) technique. ... confirm a recent infection or ...
... Captia™ Varicella-Zoster Virus (VZV) IgM ... intended for the detection of ... in human serum as an ... primary infection or reactivation. For ...
... Biotech Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked ... detection and quantitative determination of IgG antibody ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
Medicine Products: